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At a Glance Commentary 
Scientific knowledge on the subject: 
Zephyr Endobronchial Valves properly placed in segmental and sub-segmental airways 
in patients with severe heterogeneous or homogeneous emphysema with no collateral 
ventilation between target and ipsilateral lobe have been shown to decrease 
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hyperinflation by reducing target lobe volume, thereby providing clinical improvements 
in lung function, exercise tolerance and quality of life. 
 
What this study adds to the field 
This first, multicenter, prospective, randomized controlled clinical trial of the Zephyr 
Endobronchial valves (EBVs) confirms findings from 2 previous single-center RCTs that 
in patients with heterogeneous emphysema distribution and absence of collateral 
ventilation, these one-way valves improve lung function, dyspnea, exercise tolerance, 
and quality of life over current standard of care medical therapy. 
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Abstract 
Rationale: Single-center RCTs of Zephyr Endobronchial Valve (EBV) treatment have 
demonstrated benefit in severe heterogeneous emphysema. This is the first multicenter 
study evaluating this treatment approach.  
Objectives: To evaluate the efficacy and safety of Zephyr EBVs in patients with 
heterogeneous emphysema and absence of collateral ventilation. 
Methods: Prospective, multicenter 2:1 RCT of EBVs plus standard of care or standard 
of care (SoC) alone. Primary outcome at 3 months post-procedure was the percent of 
subjects with a FEV1 improvement from baseline of ≥12%.  Changes in FEV1, RV, 
6MWD, SGRQ, and mMRC were assessed at 3 and 6 months, and target lobe volume 
reduction (TLVR) on chest CT at 3 months. 
Results: Ninety seven subjects were randomized to EBV (n=65) or SoC (n=32). At 3 
months, 55.4% of EBV and 6.5% of SoC subjects had an FEV1 improvement ≥12% 
(p<0.001). Improvements were maintained at 6 months: EBV 56.3% vs SoC 3.2% 
(p<0.001), with a mean change in FEV1 at 6 months of 20.7±29.6% and -8.6±13.0%, 
respectively. 89.8% of EBV subjects had TLVR ≥350ml, mean 1.09±0.62L (p<0.001). 
Between group differences for changes at 6 months were statistically and clinically 
significant: ∆EBV–SoC for RV -700ml; 6MWD +78.7m; SGRQ -6.5 points; mMRC 
Dyspnea score -0.6 points; BODE Index -1.8 points (all p<0.05). Pneumothorax was the 
commonest adverse event, occurring in 19/65 (29.2%) of EBV subjects. 
Conclusions: EBV treatment in hyperinflated patients with heterogeneous emphysema 
without collateral ventilation resulted in clinically meaningful benefits in lung function, 
dyspnea, exercise tolerance, and quality of life, with an acceptable safety profile. 
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Introduction 
Chronic obstructive pulmonary disease (COPD) is a progressive, life-threatening, lung 
disease characterized by airflow obstruction that results in breathlessness and 
predisposes afflicted individuals to exacerbations and serious illness (1). Patients with 
advanced emphysema remain one of the most at-risk sub-populations. It is estimated 
that over 300 million people globally have COPD, with considerable dyspnea due to 
lung hyperinflation, poor quality of life, few treatment options, and a reduced life 
expectancy (2,3,4).  
 
Lung volume reduction surgery (LVRS) results in improvements in lung function, 
dyspnea, exercise tolerance, and long-term survival in appropriately selected patients 
with emphysema (5,6,7,8). Whilst LVRS has proven effective in selected populations, 
the technique is relatively under-utilized owing to concerns about the invasiveness of 
the procedure, morbidity, and the narrow patient eligibility criteria (9,10). Zephyr® 
endobronchial valves (EBV®, Pulmonx Corporation, Redwood City, CA) are one-way 
valves inserted via the bronchoscope into the airways of emphysematous lung, and are 
designed to cause lung deflation (and hence a reduction in hyperinflation) by allowing 
air and secretions out but preventing air entry.  
 
Bronchoscopic lung volume reduction with Zephyr EBVs aims to provide the benefits 
seen with LVRS but with a reduction in morbidity.  The VENT study achieved statistical 
but not clinically meaningful improvements in forced expiratory volume in 1 second 
(FEV1) and six-minute walking distance (6MWD) between EBV-treated and control 
groups (11), with post-hoc analysis showing that improvements in these outcomes were 
clinically meaningful only in patients with no collateral ventilation (CV) between the 
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target and ipsilateral lobes (11,12). Zephyr EBVs have been shown to cause target lobe 
volume reduction (TLVR) in patients without CV and where lobar occlusion is achieved 
(13,14).  Clinically and statistically meaningful benefits in multiple outcome measures 
have been demonstrated in patients with heterogeneous (15,16) as well as 
homogeneous emphysema (16,17). Two single-center randomized controlled trials 
(15,16) have reported significant benefits of Zephyr EBVs over best medical care, and 
we now report the first multi-center study in patients with heterogeneous emphysema 
and without CV. Some of the results of this study have been previously reported in 
the form of an abstract (18). 
 
Methods 
Study Conduct: This randomized, controlled trial (NCT02022683) enrolled patients 
between June 2014 and June 2016 at 17 sites across Europe. The study was approved 
by the respective Ethics Committees at each site, and conducted in accordance with the 
Declaration of Helsinki (19). All participating subjects provided written informed consent.   
 
Study Subjects: Eligible subjects were ex-smokers ≥40 years of age with severe 
emphysema. Key inclusion criteria were post-bronchodilator FEV1 of between 15% and 
45% predicted despite optimal medical management, total lung capacity (TLC) >100% 
predicted, residual volume (RV) ≥180% predicted, and a 6MWD of between 150m and 
450m (complete criteria provided in online supplement – Section E1).  High resolution 
computed tomography (HRCT) scans were analyzed at an independent imaging core 
laboratory using quantitative software (VIDA Diagnostics, Coralville, IA, USA) to 
measure lobar volumes and emphysema destruction by lobe. Heterogeneous 
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emphysema was defined as a >10% difference in destruction scores between target 
and ipsilateral lobes.  
 
Eligible patients underwent Chartis® (Pulmonx Corporation, Redwood City, CA) 
assessment to determine the presence of CV between target and adjacent lobes before 
randomization. The Chartis® Pulmonary Assessment System is a validated system 
designed to assess for the presence of collateral ventilation within isolated lung units. It 
consists of a Chartis console connected to a balloon catheter with a central channel 
which is used to occlude the target lobe, and to subsequently measure pressure and 
flow in order to calculate resistance to airflow in that lobe, and hence to quantify 
collateral ventilation (13). Figure E1 in the online supplement shows examples of CV 
negative and CV positive read-outs. Subjects who had a CV negative target were 
randomized in a 2:1 fashion (blocked design and concealed envelopes) immediately 
after the Chartis measurement into either the EBV group or the SoC group.  The 
bronchoscopy procedure for subjects randomized to SoC was terminated and subjects 
recovered appropriately as per institutional standards. Subjects randomized to the EBV 
group underwent immediate placement of Zephyr EBVs with the intention of complete 
lobar occlusion (12,20). Subjects assessed to be CV positive were excluded. See online 
supplement Sections E2 and E3 for complete details. 
 
Where there was more than one potential target lobe, the lobe with the highest 
destruction score and lowest perfusion as determined by scintigraphy was assessed for 
CV first. If the primary target lobe was CV positive, or if the CV status was not 
assessable, then the secondary target lobe was evaluated (for further information, see 
Figure E2 in the online supplement).  
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Follow-up: Subjects randomized to SoC were discharged after standard post-
bronchoscopy recovery, unless the treating physician deemed an admission necessary.  
Subjects randomized to EBVs were hospitalized for at least one day and discharged 
following a chest X-ray if there were no complications/serious adverse events (SAEs). 
Subjects were instructed to seek immediate medical attention in the event of symptoms 
of a potential pneumothorax. EBV subjects were evaluated at 45 days with a HRCT 
scan to assess TLVR, and to verify whether complete lobar occlusion had been 
achieved. If necessary (TLVR <50%, or incomplete lobar occlusion), a repeat 
bronchoscopy and valve revision/replacement was performed.  
 
Outcome Measures: All subjects were assessed at 3 months post-bronchoscopy (SoC 
and EBV). For EBV subjects who underwent valve replacement or revision based on 
their 45 day HRCT scan, follow-up occurred 3 months after the revision bronchoscopy.  
Subjects in the SoC group were given the option of exiting the study following the 6 
month evaluation if they wished to pursue EBV treatment, or to continue in follow-up 
until 12 months. Follow-up of the EBV group will continue to 24 months (see study 
scheme, Figure E3 in online supplement). 
 
The primary endpoint was the percentage of subjects in the EBV group at 3 months 
post-procedure who had an improvement in the post-bronchodilator FEV1 of ≥12% 
(protocol-defined minimal clinically important difference (MCID)) compared to the 
percentage of subjects in the SoC group. 
 
Page 12 of 66 AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 13 of 32 
Secondary endpoints included comparison between EBV and SoC groups for the 
absolute and percent changes and responder rates (percentage of subjects achieving 
the MCID) at 3 and 6 months for FEV1 (≥12%), RV (≤-430 mL), St. George’s Respiratory 
Questionnaire (SGRQ) score (≤-4 points), 6MWD (≥26 meters), modified Medical 
Research Council (mMRC) dyspnea score (≤-1 point), and for the EBV group only, the 
absolute and percent change in TLVR at 45 days post-procedure and the percent of 
subjects meeting the TLVR MCID of ≥350mL (12) relative to baseline. Safety was 
assessed through review of all adverse events solicited at all scheduled or unscheduled 
visits.  
 
Statistical Analyses: The sample size calculation of 78 subjects was based on 
proportions for the primary endpoint of a ≥12% improvement in FEV1 at 47% (EBV) and 
13% (SoC) estimated from the VENT study (11), a 2:1 randomization, 80% power, 
alpha = 0.05, a two-sided Chi-Square test, and 15% drop-out rate.  For the intention-to-
treat (ITT) analysis, missing data were imputed using the last observation carried 
forward method. All statistical analyses were performed using SAS 9.4 (SAS Institute, 
Cary NC). Absolute and percent changes from baseline were analyzed using a fixed-
effect one-way ANOVA (or ANCOVA with baseline as a covariate) model for normally 
distributed data; otherwise the Wilcoxon Rank-Sum test was used. Categorical variables 
were analyzed using a Chi-Square test. Details of the analysis populations in Section 
E4 in online supplement. 
 
Results 
Two hundred and seventy-three (273) subjects were screened, with 125 subjects 
meeting the inclusion/exclusion criteria. A total of 97 subjects deemed to be CV 
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negative were randomized, 65 subjects to EBVs and 32 to SoC (see CONSORT 
diagram, Figure E4 in online supplement). The median(range) number of randomized 
subjects per center was 5(1-14). Baseline characteristics were similar in both groups, 
although the EBV group reported a worse respiratory related quality of life (p=0.042) 
and absolute but not percent predicted FEV1 (p=0.008). See Table 1 and Table E1 in 
online supplement.  
 
Treatment details: A median of 4 valves (range 2 to 8) per subject were implanted in the 
65 EBV subjects. Treatment distributions were 52% left upper lobe, 22% left lower lobe, 
15% right upper lobe, 8% right upper and right middle lobe combined, and 3% right 
lower lobe. The median hospital stay for the treatment visit was 4 days (range 1 to 49 
days) for the EBV group and 1 day (range 1 to 3 days) for the SoC group. At 45 days 
post-procedure, 89.8% of subjects achieved a TLVR of ≥350ml, with a mean of 1.09 ± 
0.62L (p<0.001). Individual subject TLVR changes are provided in Figure E5 in the 
online supplement. Eighteen subjects underwent a repeat bronchoscopy, 17 of whom 
had a revision procedure, and 12 of those subsequently developed significant TLVR. 
 
Primary outcome: At 3 months post-procedure, responder rates (≥12% improvement 
from baseline in FEV1) in the ITT population were 55.4% in the EBV group and 6.5% in 
the SoC group (p<0.001), and for the per protocol (PP) population were 66.7% and 
6.7%, respectively (p<0.001). These differences were maintained at 6 months: ITT (EBV 
vs SoC) 56.3% vs 3.2% (p<0.001), and PP 66.3% vs 3.3% (p<0.001), respectively 
(Figure 1). 
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Secondary outcomes:  Statistically and clinically significant improvements from baseline 
were seen at both 3 and 6 months in the EBV group compared to the SoC group for 
FEV1 (Figure 2a), 6MWD (Figure 2b), and SGRQ score (Figure 2c). There was a 
decrease in RV (p<0.001, Figure 2d) and BODE Index (points, p<0.001, Figure 2e) in 
the EBV vs SoC group at both 3 and 6 months. The absolute and percent changes from 
baseline at 6 months are summarized in Table 2. Changes from baseline for EBV and 
SoC groups and differences between groups for the changes for the PP population are 
provided in Tables E2 to E9 in online supplement. 
 
For each outcome measure, a significantly greater number of subjects in the EBV group 
met or exceeded the MCID (Table 3, and Table E10, and Figures E6, E7, and E8 in 
online supplement). In post-hoc analysis, 76.9% of the ITT population and 90.2% of the 
PP population achieved the MCID for at least one of FEV1, 6MWD, and SGRQ at 6 
months.  Following the 6 month evaluation, 30 of the 32 SoC subjects exited the study 
and opted for EBV treatment. 
 
Safety outcomes: At 6 months, there were 44 respiratory related SAEs in 31 (47.7%) 
subjects in the EBV group compared to 4 events in 3 (9.4%) subjects in the SoC group 
(p<0.001, Fishers test), with most events occurring within 30 days of the procedure 
(Table 4). In the EBV group, the most common SAE was pneumothorax, which was 
managed according to a protocolized pneumothorax management flow chart (21, and 
Figure E9 in online supplement). Other respiratory related SAEs during the first 30 days 
in the EBV group included dyspnea (7.7%), COPD exacerbation (4.6%), and pneumonia 
(4.6%). A summary of all respiratory and non-respiratory adverse events is provided in 
Tables E11 and E12 in the online supplement.  
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Pneumothorax: Over the 6 month follow-up period, there were 20 pneumathoraces in 
19/65 (29.2%) EBV subjects, with a median time to onset of 1 day. Table E13 in the 
online supplement shows pneumothorax rate by lobe treated. In 14 subjects, the 
pneumothorax required an intervention and/or hospitalization and was therefore 
considered a SAE. Pneumothorax was managed by observation only in 8 cases, and 
placement of chest drains in 11 cases. In one case, the air leak was addressed 
surgically. Seven subjects underwent a second bronchoscopy for an adverse event, 5 
for valve removal for pneumothorax management, one for valve replacement a day after 
the initial procedure due to expectoration of a valve, and one for loss of effect.  One 
EBV subject died of in-hospital cardiac arrest as a complication of pneumothorax. There 
were no differences in any outcome measure at 3 or 6 months in the EBV cohort 
between subjects who experienced a pneumothorax (n=19) and those that did not 
(n=46). See tables E14 and E15 in the online supplement. 
 
Discussion 
This is the first multicenter, prospective RCT of Zephyr EBV treatment in patients with 
severe heterogeneous emphysema and absence of collateral ventilation. We found 
statistically and clinically significant improvements in lung function, exercise capacity, 
and quality of life associated with Zephyr EBV treatment compared with standard of 
care. Ninety percent of subjects experienced TLVR, indicating appropriate selection of 
CV negative patients and effective occlusion of the target lobe following EBV 
placement. Of significance, the EBV group had improvements that exceeded the MCIDs 
for FEV1, SGRQ, RV, 6MWD, and mMRC at 6 months post-treatment.   
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Post-hoc analysis of the VENT study (11,12) demonstrated the critical importance of the 
absence of CV and achieving complete lobar occlusion as necessary elements for 
successful lung volume reduction with EBVs. Whilst visual evaluation of fissure 
completeness has been useful in patient selection for bronchoscopic lung volume 
reduction with Zephyr EBVs (15), the physiologic assessment of air flow using the 
Chartis System has been more reliable (13,16). Using this approach, Klooster et al (16) 
successfully demonstrated significant improvements in lung function and exercise 
capacity in patients with severe emphysema characterized by an absence of CV. 
Similarly, Valipour et al (17) reported benefits in patients with homogeneous 
emphysema. The findings of the present multicenter RCT provide further confirmation 
that patients carefully selected for absence of CV experience significant, meaningful 
reduction in treated lobar volumes (mean 1.09 ± 0.62L, p<0.001) with benefits in lung 
function, dyspnea, exercise capacity, and quality of life following Zephyr EBV 
placement.  
 
The magnitude of benefits seen in this study are comparable to those observed after 
LVRS (8), but with reduced morbidity. The mean change presented here in the 6MWD, 
a patient-centered outcome, is three times the MCID, and similar to values reported 
from a single center RCT (16). Zephyr EBV treatment has the added benefits of being 
suitable for both upper and lower lobe disease, as well as homogeneous disease (17), 
and is a reversible procedure. Valves were permanently removed in 7 subjects in our 
study with no associated complications.  
 
There were a greater number of serious adverse events in the early post-procedure 
period (within the first 30 days) in the EBV group than in the SoC group (Table 4).  
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Pneumothorax was the most common adverse event, and was managed according to 
published guidelines (21). The occurrence of pneumothoraces and air leaks is a 
common side-effect of thoracic procedures, ranging from 4% to 42% after CT-guided 
biopsy (22,23), 11.6% for endobronchial coil treatment (24), and up to 90% of patients 
within 30-days of LVRS (25). The frequency of pneumothorax in the present study 
(21.5%) was similar to other published Zephyr EBV treatment studies (16,17), and the 
occurrence of pneumothorax does not appear to negatively impact clinical outcomes 
(26).  Of note, 94% (30/32) of the control subjects opted to exit the study and receive 
Zephyr EBV treatment after the 6 month evaluation. 
 
Previous retrospective analyses have demonstrated a survival advantage where TLVR 
is achieved after Zephyr EBV placement (27,28,29). A reduction of more than 1 point in 
the BODE Index has been associated with a significant decrease in mortality (30,31) 
and the difference between groups in the change in BODE Index in this prospective trial 
was -1.8 points. This is compatible with the recent report by Klooster at al (32), and 
raises the hope of improved survival in our subjects. This will need to be confirmed in 
future studies and with longer follow up data. 
 
One limitation of this study is the follow-up out to only 6 months, though earlier single 
center RCTs have reported 1-year follow-up data, demonstrating the durability of this 
treatment (33,34).  Subjects in the EBV group will be followed out to 2 years, important 
for capturing events that may be infrequent in a 6 month window, such as exacerbations 
or mortality.   Another limitation is the absence of a sham bronchoscopy in the SoC 
group, since the treatment involves an intervention with associated adverse events and 
the potential for a placebo effect. However, unlike other interventional devices for BLVR, 
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the benefit of EBV treatment using a sham control has previously been demonstrated 
(15), and patients in the SoC arm in our study did undergo bronchoscopy for the 
purposes of Chartis examination (although this does not mitigate against any placebo 
effect associated with actual valve implantation).  
 
Another potential limitation is the lack of mandatory pulmonary rehabilitation in the 
period prior to trial entry. Given the randomized nature of the trial, any changes or lack 
thereof associated with the potentially variable provision of pre-procedure PR should be 
balanced across the 2 groups, and therefore would not be expected to be a significant 
factor in any between group differences. 
 
Whilst there was an apparent imbalance in the absolute FEV1, and to a lesser extent 
SGRQ, at baseline between the two groups (although not in the percent predicted 
FEV1), which could have affected outcome, ANCOVA models with baseline values as 
the covariate resulted in the same p-values as when using the t-test for all secondary 
endpoints, indicating that the group differences (EBV vs. SoC) are there despite the 
groups having different baseline values. 
 
The benefits of EBV treatment for patients with severe heterogeneous emphysema 
reported here, and for homogeneous patients previously reported by Valipour et al (17), 
demonstrate that EBV placement is an effective treatment option in patients without CV 
regardless of emphysema distribution. The success of the treatment requires accurate 
patient selection including correct determination of the absence of CV between target 
and adjacent lobes, and expertise in the management of procedural complications.  
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Conclusion 
EBV treatment in hyperinflated subjects with heterogeneous emphysema without CV in 
the target lobe results in clinically meaningful and statistically significant benefits in lung 
function, dyspnea, exercise tolerance, and quality of life over current standard of care 
medical therapy. Benefits are in line with those seen with LVRS, and the consistent trial 
results, potential reduction in post-procedure morbidity, and reversibility of the 
procedure position Zephyr EBV treatment as a viable treatment option in those who 
remain symptomatic on maximal medical therapy.  
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Figure 1: Primary Endpoint - Percent of subjects achieving a 12% or greater Improvement in 
FEV1 (L) at 3 Months. 
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Figure 2: Absolute changes from Baseline in key outcome measures at 3 and 6 months 
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Legend to Figure 2:  Data presented are mean ± SEM for changes from baseline to 3 and 6 
months post bronchoscopy for EBV (□), SoC (○), and difference between EBV and SoC (Δ). 
Figure 2a: FEV1 (L); Figure 2b: 6-Minute Walk Distance (m); Figure 2c: RV (L); Figure 2d: St. 
George’s Respiratory Questionnaire; and Figure 2e: BODE Index. 
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Table 1: Baseline demographics and clinical characteristics 
Variable EBV  
(n=65) 
SoC  
(n=32) 
t-test 
p-value 
Gender 37 Males / 28 Females 21 Males / 11 Females NS 
Age (years) 64.9 ± 8.0 63.0 ± 6.0 NS 
BMI (kg/m
2
) 23.7 ± 4.4 24.3 ± 5.3 NS 
Smoking history (pack years)  42.0 ± 21.5 42.0 ± 20.2 NS 
Clinical Characteristics 
GOLD Stage 
Stage III: 26 (40%) 
Stage IV: 39 (60%)  
Stage III: 18 (56%) 
Stage IV: 14 (44%) 
NS 
Emphysema score of the target lobe 
at -910 HU* 
69.3 ± 9.3 68.4 ± 11.2 NS 
Heterogeneity Index between target 
and ipsilateral lobe(s) † 
21.8 ± 14.6 25.5 ± 15.8 NS 
Forced Expiratory Volume in 1 sec. (L) 0.78 ± 0.24 0.94 ± 0.31 0.008 
Forced Expiratory Volume in 1 sec. (% 
predicted) 
29.8 ± 9.2 32.2 ± 8.4 NS 
Residual Volume (% predicted) 249.4 ± 51.8 241.0 ± 41.4 NS 
Total Lung Capacity (% predicted) 139.0 ± 18.9 137.3 ± 12.5 NS 
6 Minute Walk Distance (m) 282 ± 94 320 ± 92 NS 
SGRQ Total score ‡ 64.3 ± 14.4 58.1 ± 13.3 0.042 
mMRC score § 3.00 ± 0.77 2.88 ± 0.83 NS 
BODE Index score ** 6.14 ± 1.68 5.55 ± 1.77 NS†† 
Values are means ± SD.  
* Emphysema destruction score was assessed as the percentage of voxels of less than −910 
Hounsfield units on CT. 
† Heterogeneity Index was assessed as the difference in the Emphysema score between the target 
and the ipsilateral lobe. 
‡ St. George’s Respiratory Questionnaire (SGRQ) scores range from 0 to 100, with higher scores 
indicating worse quality of life.   
§ Modified Medical Research Council dyspnea (mMRC) scores scale ranges from 0 to 4, with higher 
scores indicating more severe dyspnea. 
** BODE Index score ranges from 0 to 10 based on a multidimensional scoring system to include FEV1, 
body-mass index, 6 Minute Walk Distance, and the modified MRC dyspnea score. Higher scores 
denote a greater risk of mortality.  
††: Wilcoxon signed-rank test. 
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Table 2: Mean changes from baseline in secondary outcome measures at 6-months (ITT) 
Outcome Measure Change from 
Baseline 
EBV 
(n=65) 
SoC 
(n=32) 
Δ EBV – SoC 
Mean [95% CI] 
p-value* 
FEV1 Liters (L) 0.14 ± 0.24 -0.09 ± 0.14 0.2 [0.1, -0.3] <0.001 
 Percent (%) 20.7 ± 29.6 -8.6 ± 13.0 29.3 [18.3, -40.4] <0.001 
RV  Liters (L) -0.66 ± 1.04 0.01 ± 0.79 -0.7 [-1.1, -0.3] 0.002 
6MWD Meters 36.2 ± 76.9 -42.5 ± 68.2 78.7 [46.3, 111.0] <0.001 
SGRQ total score Points -7.2 ± 15.1 -0.7 ± 10.4 -6.5 [-12.4, -0.6] 0.031 
mMRC Grade Points -0.56 ± 1.04 0.00 ± 0.86 -0.6 [-1.0, -0.1] 0.010 
BODE Index score Points --0.97 + 2.01 0.79 ± 1.17 -1.8 [-2.6, -0.9] <0.001
†
 
Values are means ± SD.  
*: Two sample t test  
†: Wilcoxon signed-rank test 
ANCOVA with baseline as covariate did not impact any outcomes 
 
 
 
 
Table 3: MCID responders for key outcome measures in the ITT population at 6 months 
Variable EBV  SoC  p-value
*
 
FEV1 (L): (MCID ≥ +12%)
35,36 
36/64 (56.3%) 1/31 (3.2%) < 0.001 
RV (ml): (MCID ≤ -430 mL)
37 
37/64 (57.8%) 8/31 (25.8%) 0.003 
SGRQ: (MCID ≤ -4 points)
38 
35/62 (61.7%) 11/32 (34.4%) 0.042 
6MWD: (MCID≥ +26 meters)
39 
33/63 (52.4%) 4/31 (12.9%) <0.001 
mMRC: (MCID ≤ -1 point)
40 
29/64 (43.8%) 7/31 (22.6%) 0.032 
FEV1: Forced Expiratory Volume in 1 second; RV: Residual Volume; SGRQ: St. George’s Respiratory 
Questionnaire; 6MWD: Six-Minute Walk Distance; mMRC: Modified Medical Research Council 
Dyspnea score 
*: Chi-squared test 
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Table 4: Serious adverse events during 6 months of follow up 
 EBV (n=65) SoC (n=32) 
Event 
≤30 days 
Events 
≤30 days 
Subjects 
(%) 
>30 days 
to 
6 months 
Events 
>30 days 
to 
6 months 
Subjects 
(%) 
≤30 days 
Events 
≤30 days 
Subjects 
(%) 
>30 days 
to 
6 months 
Events 
>30 days 
to 
6 months 
Subjects 
(%) 
Pneumothorax 13 
13 
(20.0%) * 
2
¶
 2 (3.1%) 0 0 0 0 
Dyspnea 6 5 (7.7%) 2 2 (3.1%) 0 0 0 0 
Pneumonia 3  3 (4.6%) 3 3 (4.6%) 0 0 1 1 (3.1%) 
COPD Exacerbation 3 3 (4.6%) 4 3 (4.6%) 0 0 3 2 (6.3%) 
Subcutaneous 
emphysema  
1 1 (1.5%) 0 0 0 0 0 0 
Hemoptysis 1 1 (1.5%) 0 0 0 0 0 0 
Inhaled foreign body 1 1 (1.5%) 0 0 0 0 0 0 
Lower Respiratory 
Tract Infection 
1 1 (1.5%) 0 0 0 0 0 0 
Death 1 1 (1.5%)ǂ 0 0 0 0 0 0 
Bronchospasm 0 0 2 1 (3.1%) 0 0 0 0 
Influenza 0 0 1 1 (1.5%) 0 0 0 0 
EBV removal 0 0 1 1 (1.5%) 0 0 0 0 
Serious Adverse Events were events leading to death or to serious deterioration in health that resulted in a life-
threatening illness or injury, a permanent impairment of a body structure or body function, hospitalization or 
prolongation of existing hospitalization, or medical or surgical intervention to prevent permanent impairment to body 
structure or body function. 
  
¶:  
One event occurred 58 days after initial placement and 3 days after a valve replacement procedure (valve previously 
removed due to pneumothorax); one event occurred 83 days after valve placement procedure. 
ǂ: Also included in the count of Pneumothorax; subject died of cardiac arrest during hospitalization for a pneumothorax 
*: p=0.004 Fisher’s Exact Test (EBV vs SoC at ≤30 days) 
 
  
Page 26 of 66 AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 27 of 32 
 
 
REFERENCES 
 
1. GOLD 2017 Global Strategy for the Diagnosis, Management and Prevention of COPD 
http://goldcopd.org/ 
2. López‐ópez2017 Global Strategy for the Diagnosis, Management and Prevention 
Respirology. 2016; 21(1): 14-23. 
3. Mathers CD, Loncar D (2006) Projections of Global Mortality and Burden of Disease from 
2002 to 2030. PLoS Med 3(11): e442.  
4. Davies Adeloye, Stephen Chua, Chinwei Lee, Catriona Basquill, Angeliki Papana, Evropi 
Theodoratou, Harish Nair, Danijela Gasevic, Devi Sridhar, Harry Campbell, Kit Yee Chan, 
Aziz Sheikh, Igor Rudan, and Global Health Epidemiology Reference Group (GHERG) 
Global and regional estimates of COPD prevalence: Systematic review and meta–analysis. 
J Glob Health. 2015 Dec; 5(2): 020415.  
5. Fishman A, Martinez F, Naunheim K, Piantadosi S, Wise R, Ries A, Weinmann G, Wood 
DE; National Emphysema Treatment Trial Research Group. A randomized trial comparing 
lung-volume-reduction surgery with medical therapy for severe emphysema. N Engl J Med 
2003; 348: 2059-2073 
6. Geddes D, Davies M, Koyama H, Hansell D, Pastorino U, Pepper J, Agent P, Cullinan P, 
MacNeill SJ, Goldstraw P. Effect of lung-volume-reduction surgery in patients with severe 
emphysema. N Engl J Med 2000; 343: 239-245. 
7. Miller JD, Berger RL, Malthaner RA, Celli BR, Goldsmith CH, Ingenito EP, Higgins D, 
Bagley P, Cox G, Wright CD. Lung volume reduction surgery vs. medical treatment for 
Page 27 of 66  AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 28 of 32 
patients with advanced emphysema. Chest 2005; 127: 1166-1177. 
8. Washko GR, Fan VS, Ramsey SD, Mohsenifar, Martinez F, Make BJ, Scuirba FC, Criner 
GJ, Minai O, DeCamp MM, Reilly JJ; National Emphysema Treatment Trial Research 
Group. The Effect of Lung Voume Reduction Surgery on Chronic Obstructive Pulmonary 
Disease Exacerbations. Am J Respir Crit Care Med. 2008; 177: 164-169. 
9. DeCamp Jr, Malcolm M, Mckenna Jr, RJ, Deschamps CC, Krasna MJ. Lung volume 
reduction surgery: technique, operative mortality, and morbidity. Proc Am Thorac Soc. 
2008; 5: 442-446. 
10. DeCamp Jr, MM, Lipson, D, Krasna M, Minai OA, McKenna Jr, RJ, Thomashow BM. The 
evaluation and preparation of the patient for lung volume reduction surgery. Proc Am 
Thorac Soc. 2008; 5(4): 427-431. 
11. Sciurba FC, Ernst A, Herth FJF, Strange C, Criner GJ, Marquette CH, Kovitz, KL, 
Chiacchierini RP, Goldin J, McLennan G. A randomized study of endobronchial valves for 
advanced emphysema. N Engl J Med 2010; 363: 1233 – 1244. 
12. Herth FJF, Noppen M, Valipour A, Leroy S, Vergnon J, Ficker JH, Egan JJ, Gasparini S, 
Agusti C, Holmes-Higgin D, Ernst A. Efficacy predictors of lung volume reduction with 
Zephyr valves in a European cohort. Eur Respir J 2012; 39: 1334 -1342. 
13. Herth FJ, Eberhardt R, Gompelmann D, Ficker JH, Wagner M, Ek L, Schmidt B, Slebos DJ. 
Radiological and clinical outcomes of using Chartis to plan endobronchial valve treatment. 
Eur Respir J. 2013; 41(2):302–308. 
14. Valipour A, Herth FJ, Burghuber OC, Criner G, Vergnon JM, Goldin J, Sciurba F, Ernsy A; 
VENT Study Group. Target lobe volume reduction and COPD outcome measures after 
endobronchial valve therapy. Eur Respir J. 2014; 43(2):387–396. 
Page 28 of 66 AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 29 of 32 
15. Davey C, Zoumot Z, Jordan S, McNulty WH, Carr DH, Hind MD, Hansell DM, Rubens MB, 
Banya W, Polkey MI, Shah PL, Hopkinson NS. Bronchoscopic lung volume reduction with 
endobronchial valves for patients with heterogeneous emphysema and intact interlobar 
fissures (the BeLieVeR-HIFi study): a randomised controlled trial. Lancet. 2015; 386: 
1066–1073. 
16. Klooster K, ten Hacken NHT, Hartman JE, Kerstjens HAM, van Rikxoort EM, Slebos DJ. 
Endobronchial Valves for Emphysema without Interlobar Collateral Ventilation. N Engl J 
Med 2015; 373:2325-2335 
17. Valipour A, Slebos DJ, Herth F, Darwiche K, Wagner M, Ficker JH, Petermann C, Hubner 
RH, Stanzel F, Eberhardt R; IMPACT Study Team. Endobronchial valve therapy in patients 
with homogeneous emphysema: results from the IMPACT study. Am J Respir Crit Care 
Med 2016; 194: 1073–1082. 
18. Kemp SV, Slebos DJ, Kirk A, Kornaszewska M, Carron K, Ek L, Mal H, Pison C, Downer 
NJ, Broman G, Darwiche K, Rao J, Hubner R-H, Trosini-Desert V, Eberhardt R, Herth FJF, 
Derom E, and Marquette CH. A Multicenter, Prospective, Randomized, Controlled Trial of 
Endobronchial Valve Treatment vs standard of Care in Heterogeneous Emphysema 
(Transform). Am J Respir Crit Care Med. 2017; 19S: A6740. 
19. World Medical Association. World Medical Association Declaration of Helsinki Ethical 
Principles for Medical Research Involving Human Subjects. JAMA. 2013;310(20):2191-
2194. 
20. Slebos Dirk-Jan, Shah PL, Herth FJF, Valipour A. Endobronchial Valves for Endoscopic 
Lung Volume Reduction: Best Practice Recommendations from Expert Panel on 
Endoscopic Lung Volume Reduction. Respiration. 2017; 93:138-150.  
Page 29 of 66  AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 30 of 32 
21. Valipour A, Slebos DJ, de Oliveira HG, Eberhardt R, Freitag L, Criner GJ, Herth FJ: Expert 
statement: pneumothorax associated with endoscopic valve therapy for emphysema – 
potential mechanisms, treatment algorithm, and case examples. Respiration 2014; 87:   
513–521. 
22. Laspas F, Roussakis A, Efthimiadou R, Papaioannou D, Papadopoulos S, Andreou J. 
Percutaneous CT-guided fine-needle aspiration of pulmonary lesions: results and 
complications in 409 patients. J Med Imaging Radiat Oncol. 2008; 52: 458–462. 
23. Hiraki T, Mimura H, Gobara H, Shibamoto K, Inoue D, Matsui Y, Kanazawa S. Incidence of 
and risk factors for pneumothorax and chest tube placement after CT fluoroscopy-guided 
percutaneous lung biopsy: retrospective analysis of the procedures conducted over a 9-
year period. AJR Am J Roentgenol. 2010; 194: 809–814. 
24. Sciurba FC, Criner GJ, Strange C, Shah PL, Michaud G, Connolly TA, Deslée G, Tillis WP, 
Delage A, Marquette CH, Krishna G, Kalhan R, Ferguson JS, Jantz M, Maldonado F, 
McKenna R, Majid A, Rai N, Gay S, Dransfield MT, Angel L, Maxfield R, Herth FJ, Wahidi 
MM, Mehta A, Slebos DJ; RENEW Study Research Group. Effect of Endobronchial Coils 
vs Usual Care on Exercise Tolerance in Patients with Severe Emphysema: The RENEW 
Randomized Clinical Trial. JAMA. 2016; 315(20):2178-2189. 
25. DeCamp MM, Blackstone EH, Naunheim KS, Krasna MJ, Wood DE, Meli YM, McKenna RJ 
Jr; NETT Research Group. Patient and surgical factors influencing air leak after lung 
volume reduction surgery: lessons learned from the National Emphysema Treatment Trial. 
Ann Thorac Surg. 2006; 82(1): 197-207. 
26. Gompelmann D, Herth FJ, Slebos DJ, Valipour A, Ernst A, Criner GJ, Eberhardt R. 
Pneumothorax following endobronchial valve therapy and its impact on clinical outcomes in 
Page 30 of 66 AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 31 of 32 
severe emphysema. Respiration. 2014; 87(6):485–491. 
27. Hopkinson NS, Kemp SV, Toma TP, Hansell DM, Geddes DM, Shah PL, Polkey MI. 
Atelectasis and survival after bronchoscopic lung volume reduction for COPD. Eur Respir 
J. 2011 Jun; 37(6):1346-51. 
28. Garner J, Kemp SV, Toma TP, Hansell DM, Polkey MI, Shah PL, Hopkinson NS. Survival 
after Endobronchial Valve Placement for Emphysema: A 10-Year Follow-up Study. Am J 
Respir Crit Care Med. 2016; 15;194(4): 519-21.  
29. Venuta F, Anile M, Diso D, Carillo C, De Giacomo T, D’Andrilli A, Fraioli F, Rendina EA and 
Coloni GF. Long-term follow-up after bronchoscopic lung volume reduction in patients with 
emphysema. Eur Respir J. 2013; 39(3): 1084 – 1089. 
30. Celli BR, Cote CG, Marin JM, Casanova C, Montes de Oca M, Mendez RA, Pinto Plata V, 
Cabral HJ. The body-mass index, airﬂow obstruction, dyspnea, and exercise capacity index 
in chronic obstructive pulmonary disease. N Engl J Med 2004; 350: 1005–1012. 
31. Martinez FJ, Han MK, Andrei AC, Wise R, Murray S, Curtis JL, Sternberg A, Criner G, Gay 
SE, Reilly J, Make B, Reis AL, Sciurba F, Weinmann G, Mosenifar Z, DeCamp M, Fishman 
AP, Celli BR; National Emphysema Treatment Trial Research Group. Longitudinal change 
in the BODE index predicts mortality in severe emphysema. Am J Respir Crit Care Med. 
2008;178: 491–499. 
32. Klooster K, Hartman JE, ten Hacken NHT, and Slebos DJ. Improved Predictors of Survival 
after Endobronchial Valve Treatment in Patients with Severe Emphysema. Am J Respir 
Crit Care Med. 2017; 195: 1272 – 1274. 
33. Klooster K, Hartman JE, Ten Hacken NH, Slebos DJ. One-Year Follow-Up after 
Endobronchial Valve Treatment in Patients with Emphysema without Collateral Ventilation 
Page 31 of 66  AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 32 of 32 
Treated in the STELVIO Trial. Respiration. 2017;93(2):112-121. 
34. Zoumot Z, Davey C, Jordan S, McNulty WH, Carr DH, Hind MD, Polkey MI, Shah PL, 
Hopkinson NS. Endobronchial valves for patients with heterogeneous emphysema and 
without interlobar collateral ventilation: open label treatment following the BeLieVeR-HIFi 
study. Thorax. 2017; 72(3):277-279. 
35. Haniana NA, Celli BR, Donohue JF, Martin UJ. Bronchodilator Reversibility in COPD. 
Chest. 2011; 140:1055-1063. 
36. Donohue JF. Minimal clinically important differences in COPD lung function. COPD. 2005; 
2(1):111-24. 
37. Hartman JE, Ten Hacken NH, Klooster K, Boezen HM, de Greef MH, Slebos DJ. The 
minimal important difference for residual volume in patients with severe emphysema. Eur 
Respir J. 2012;40(5):1137-41. 
38. Jones P.W. Interpreting thresholds for a clinically significant change in health status in 
asthma and COPD. Eur Respir J. 2002; 19:398–404. 
39. Puhan MA, Chandra D, Mosenifar Z, Ries A, Make B, Hansel NN, Wise RA, Scruiba F for 
the NETT Research Group. The minimal important difference of exercise tests in severe 
COPD. Eur Respir J. 2011;37(4):784-90. 
40. Gross NJ. Chronic obstructive pulmonary disease outcome measurements: what’s 
important? What’s useful? Proc Am Thorac Soc. 2005; 2(4):267-71. 
Page 32 of 66 AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 1 of 34 
Supplement to Kemp et al_TRANSFORM MSS_FINAL_26JUN2017  
 
 
Online Data Supplement 
 
 
A Multicenter RCT of Zephyr® Endobronchial Valve Treatment in Heterogeneous 
Emphysema (TRANSFORM) 
 
Samuel V Kemp1,10, Dirk-Jan Slebos2, Alan Kirk3, Malgorzata Kornaszewska4, Kris 
Carron5, Lars Ek6, Gustav Broman7, Gunnar Hillerdal7, Herve Mal8, Christophe Pison9, 
Amandine Briault9, Nicola Downer10, Kaid Darwiche11, Jagan Rao12, Ralf-Harto 
Hübner13, Christof Ruwwe-Glosenkamp13, Valéry Trosini-Desert14, Ralf Eberhardt15, 
Felix J Herth15, Eric Derom16, Thomas Malfait16, Pallav L Shah1, Justin L Garner1, Nick 
H ten Hacken2, Hazem Fallouh4, Sylvie Leroy17, and Charles H Marquette17 for the 
TRANSFORM Study Team* 
 
 
 
This supplementary material is provided by the authors to give readers additional information 
relating to the above-mentioned work. 
  
Page 33 of 66  AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 2 of 34 
Supplement to Kemp et al_TRANSFORM MSS_FINAL_26JUN2017  
 
*TRANSFORM Study Team 
  
Clinical Site Investigators and Study Coordinator 
1 Royal Brompton Hospital, London, 
United Kingdom 
Samuel Kemp, Pallav L Shah, Justin Garner, Dingani 
Mpoko, Zainab Sanni-Alashe 
2 University Medical Center Groningen, 
Groningen, the Netherlands 
Dirk-Jan Slebos, Nick Ten Hackens, Karin Klooster, 
Jorine Hartman, Wouter Heero van Geffen 
3 West of Scotland Regional Heart & Lung 
Center, Golden Jubilee National 
Hospital, Glasgow, United Kingdom 
Alan Kirk, Julie Buckley, David Patton, Elizabeth Boyd, 
Elaine Matthews 
4 University Hospital of Wales, Cardiff, 
United Kingdom 
Margaret Kornaszewska, Hazem Fallouh, Helen Dyer, 
Joseph George, Hatem Naase, Azin Salimian, Jaqueline 
Holder 
5 AZ Delta, Menen, Belgium 
Kris Carron, Ingel Demedts, Melissa Masschelin, Lieke 
Seynaeve, Lies Breyne 
6 Skane University Hospital, Lund, Sweden Lars Ek, Johan Svahn, Pernilla Neglén, Charlotta Zyto 
7 Uppsala University Hospital, Uppsala, 
Sweden 
Gunnar Hillerdal, Gustav Broman, Elisabeth 
Bernspång, Helen Wallstedt 
8 Hôpital Bichat, Paris, France 
Hervé Mal, Armelle Marceau, Marie Christine 
Dombret, Yolande Costa 
9 Centre Hospitalier Universitaire, 
Grenoble, France 
Christophe Pison, Francois Arbib, Amandine Briault, 
Marie Jondot, Sebastien Quetant, Cècile Cherion, 
Anne-Lise Schneider 
10 King's Mill Hospital, Sherwood Forest 
Hospitals NHS, Sutton in Ashfield, 
United Kingdom 
Nicola Downer, Samuel Kemp, Lynne Allsop, Andrea 
Palfreman 
11 Ruhrlandklinik, University Clinic Essen, 
Essen, Germany 
Kaid Darwiche, Diana Friedrich, Ulrike Sampel, Jane 
Winantea, Hilmar Kuehl, Ruediger Michael Karpf-
Wissel, Stephan Eisenmann, Jennifer Thälker, Ulrike 
Kaiser, Filiz Özkan, Birte Schwarz 
12 Sheffield Teaching Hospital NHS 
Foundation Trust, Sheffield, the UK 
Jagan Rao, Janet Middle, Kay Housley, Esther 
Ludbrook, Allah Dino Keerio, Pene Fati 
13 Charité Universitätsmedizin Berlin 
Charité Campus Virchow-Klinikum, 
Berlin, Germany 
Ralf-Harto Hübner, Christof Ruwwe-Glosenkamp, 
Ulrike Föllmer, Melanie Wegemund, Tamar 
Zhamurashvili, Nora Grosse Darrelmann, Sandra Korge 
Page 34 of 66 AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 3 of 34 
Supplement to Kemp et al_TRANSFORM MSS_FINAL_26JUN2017  
14 Groupe Hospitalier Pitié Salpétrière, 
Paris, France 
Valéry Trosini-Desert, Juan Alejandro Cascón 
Hernández, Gwenaël Le Breton 
15 Thoraxklinik, Universitäts klinikum, 
Heidelberg, Germany 
Ralf Eberhardt, Felix Herth, Konstantina Kontogianni, 
Daniela Gompelmann, Brigitte Rump, Michaela 
Korthöber, Marie-Therese Schuster 
16 Ghent University Hospital, Ghent, 
Belgium 
Eric Derom, Thomas Malfait, Bénédicte Demeyere, 
Stefanie Vermeersch, Anja Delporte 
17 Hôpital Pasteur, Nice, France 
Charles-Hugo Marquette, Ariane Guillemart, Michèle 
Benhayoun, Johana Pradelli, Sylvia Korzeniewski, 
Claude Clary, Charles Leheron, Arfi Thierry, Sylvie 
Leroy, Fernand Macone, Céline Sanfiorenzo, Michel 
Poudenx, Pierre Wolter, Brigitte Pays, Jennifer 
Griffonnet, Virgine Roux, Casamitjana Laure, Brigitte 
Pays, Chantal Gutierrez, Maureen Fontaine 
 
 
 
  
Page 35 of 66  AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 4 of 34 
Supplement to Kemp et al_TRANSFORM MSS_FINAL_26JUN2017  
Table of Contents for Online Data Supplement 
 
Section E1: Study Subjects: Inclusion and Exclusion Criteria 
Section E2: Study Design and Methods 
Section E3: Randomization 
Section E4: Analysis population 
Section E5 :  Handling of Missing Data 
 
Tables 
Table E1:   Baseline Absolute Values 
Table E2:   Changes from Baseline to 3 Month Follow-up for ITT Population 
Table E3:   Changes from Baseline to 6 Month Follow-up for ITT Population 
Table E4:   Changes from Baseline to 3 Month Follow-up for PP Population 
Table E5:   Changes from Baseline to 6 Month Follow-up for PP Population 
Table E6: Difference between groups for Changes from Baseline to 3 Month Follow up for ITT 
Population 
Table E7: Difference between groups for Changes from Baseline to 6 Month Follow up for ITT 
Population 
Table E8: Difference between groups for Changes from Baseline to 3 Month Follow up for PP 
Population 
Table E9: Difference between groups for Changes from Baseline to 6 Month Follow up for PP 
Population 
Table E10:  MCID responders for key outcome measures in the PP population at 6 months 
Table E11:  Respiratory Adverse Events over 6 Months 
Table E12:  Non-Respiratory Adverse Events over 6 Months 
Table E13: Occurrence of pneumothorax by lobe treated  
Table E14:  EBV Subjects with pneumothorax and no pneumothorax: Difference between groups for 
changes from Baseline to 3 Month Follow up (ITT) 
Table E15:  EBV Subjects with pneumothorax and no pneumothorax: Difference between groups for 
changes from Baseline to 6 Month Follow up (ITT) 
 
Figures 
Figure E1: Examples of CV negative and CV positive read-outs from the Chartis system 
Figure E2:  Target Lobe Selection 
Figure E3:  Study Scheme 
Figure E4:  CONSORT Flow Diagram 
Figure E5:  Responders based on Target Lobe Volume Reduction of ≥350mL 
Figure E6:  Responders based on Minimal Clinically Important Difference for Forced Expiratory 
Volume in 1 Second (%) (ITT population) 
Page 36 of 66 AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 5 of 34 
Supplement to Kemp et al_TRANSFORM MSS_FINAL_26JUN2017  
Figure E7:  Responders based on Minimal Clinically Important Difference for Six-Minute Walk   
Distance (6MWD) in meters 
Figure E8:  Responders based on Minimal Clinically Important Difference for St. George’s 
Respiratory Questionnaire Score (points) 
Figure E9:  Pneumothorax treatment algorithm 
Page 37 of 66  AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 6 of 34 
Supplement to Kemp et al_TRANSFORM MSS_FINAL_26JUN2017  
Section E1: Study Subjects: Inclusion and Exclusion criteria 
 
Subjects enrolled in the Study had to meet the following Inclusion and Exclusion criteria: 
Inclusion Criteria  
1. Obtained informed consent. 
2. Diagnosis of heterogeneous emphysema with a heterogeneity index of ≥10 % between 
target and adjacent lobes. 
3. Subjects of both genders of at least 40 years of age. 
4. 15 % predicted ≤ FEV1≤ 45% predicted. 
5. TLC > 100% and RV ≥ 180% predicted. 
6. 150 meters < 6MWT < 450 meters. 
7. Non-smoker >8 weeks prior to signing the Informed Consent. 
8. CV negative target lobe. 
Additional inclusion criterion French CIP*:  
- If treated in France, Subject must be entitled to French social security 
 
Exclusion criteria 
1. Any contraindication for bronchoscopic procedure. 
2. Evidence of active pulmonary infection.  
3. History of 2 or more exacerbations requiring hospitalization over the past 12 months. 
4. Known pulmonary hypertension that according to the physician will be unsuitable for EBV 
treatment. 
5. Myocardial infarction or other relevant cardiovascular events in the past 6 months. 
6. Significant bronchiectasis seen at CT scan.  
7. Greater than two tablespoons of sputum production per day. 
8. Prior LVR or LVRS procedure. 
French CIP wording*: Prior lung transplant, median sternotomy, LVR or LVRS procedure 
(including lobectomy). 
9. Pulmonary nodule requiring follow-up within any lobe. 
10. Pregnant or nursing women. 
French CIP wording*: Subject is pregnant or lactating, or plans to become pregnant within 
the study timeframe. 
11. Hypercapnia (paCO2 >7.33 kPa). 
12. Current diagnosis of asthma. 
13. > 25mg Prednisolone (or equivalent) use/days. 
14. Any other condition that as judged by the investigator may make follow-up or 
investigations inappropriate. 
15. Evidence of pleural adhesions or earlier pulmonary surgery. 
16. Severe Bullous Emphysema (> 1/3 Hemithorax) 
17.  Any subject that according to the Declaration of Helsinki is unsuitable for enrollment. 
Additional exclusion criteria in French CIP*: 
- History of allergy to silicone and/or nitinol. 
- If treated in France, Subject is a "personne vulnerable" as defined by French regulation. 
- Simultaneous participation in another drug and/or medical device related clinical. 
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Section E2: Study Design and Methods  
Prospective, randomized, controlled, two-armed multi-center trial. Planned to enroll 78 
subjects with heterogeneous emphysema at Study centers in Europe.   
• Potential subjects with heterogeneous emphysema will be asked to sign the inform consent 
form and will thereafter initially be identified by visual read of a high-resolution computer 
tomography scan (HRCT) by the investigator. Subjects underwent baseline evaluations 
including medical history, physical examination, blood test, echocardiogram, measures lung 
volumes and lung function, scintigraphy, Six-Minute Walk Test (6MWD), and questionnaires 
including St. George’s Respiratory Questionnaire (SGRQ), modified Medical Research 
Council (mMRC) Dyspnea score, and EQ-5D. 
• Heterogeneity was confirmed using computerized software to determine the heterogeneity 
index (HI). Subjects with a HI (difference in destruction scores between potential target and 
ipsilateral lobe(s)) of ≥10% and a destruction score ≥50% in the potential target lobe were 
considered for enrollment into the Trial. In case of multiple target lobes, the lobe with the 
highest destruction score and lowest perfusion or ventilation as determined by scintigraphy 
was assessed for CV first. The scheme for target lobe determinations is shown in Figure E1. 
• All potential study candidates then underwent a Chartis assessment to determine the 
extent of collateral ventilation (CV) between target and adjacent lobes. In case of multiple 
(2) target lobes, the lobe with the highest destruction score and lowest perfusion or 
ventilation as determined by scintigraphy was assessed for CV first. If the primary target 
lobe was CV positive or if the CV status was not assessable, then the secondary target lobe 
was evaluated for CV status. Only subjects with a CV negative (low collateral flow as 
determined by the investigator) target lobe and with an exhaled volume of >100 ml were 
considered. Subjects fulfilling all the eligibility criteria were considered enrolled and were 
randomized 2:1 into either the EBV group or the SoC group.  
• Subjects randomized to EBV treatment arm had EBVs placed during a bronchoscopy 
procedure (under general anesthesia or sedation) to achieve lobar occlusion. Subjects in the 
SoC arm received standard treatment.  
• Subjects in whom EBV were placed were monitored at the hospital at least 24 hours 
following valve placement to screen for signs of volume reduction, pneumothorax and any 
other side effects or complications and had a chest X-ray performed immediately prior to 
discharge. Following discharge, the subjects were recommended to avoid anything else but 
mild physical activity and bedrest for additional four days by the treating physician. Cough 
suppressants could be prescribed prophylactically.  
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Figure E1: Examples of CV negative and CV positive read-outs from the Chartis system 
 
CV Negative (CV-) Chartis assessment 
 
 
CV Positive (CV+) Chartis assessment 
 
 
 
 
Page 40 of 66 AJRCCM Articles in Press. Published on 08-September-2017 as 10.1164/rccm.201707-1327OC 
 Copyright © 2017 by the American Thoracic Society 
Page 9 of 34 
Supplement to Kemp et al_TRANSFORM MSS_FINAL_26JUN2017  
Figure E2: Target Lobe Selection 
 
 
Note: RML is not a target lobe by itself. When RML is considered for treatment this will only be 
in combination with RUL.  
 
 
• EBV group subjects had a HRCT performed at 45 days after the procedure to verify technical 
success of valve placement. Valve adjustment or valve replacement, if indicated to be 
necessary as per the HRCT, was considered part of the study procedure.  In the case of a 
secondary valve procedure, the follow-up schedule was calculated from the date of the 
latest valve procedure. Valve adjustment/replacement could be performed only once for a 
study participant within the trial. A valve adjustment or valve replacement procedure was 
considered if:   
1. The 45-day HRCT scan, as read by the core radiology reading laboratory and 
measured using software designed to evaluate HRCT changes, showed less than 50% 
volumetric reduction in the EBV-treated lobe. 
2. The 45-day HRCT scan, as read by the core radiology reading laboratory, 
demonstrated signs indicative of incomplete occlusion, including no valve in a 
segmental airway, anatomic variation resulting in the valve not occluding accessory 
branches, leakage around the valve, and incorrect placement.  
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In addition to verifying technical success as judged by the HRCT scan, the TLVR was 
calculated relative to baseline. 
• Subjects in both EBV and SoC arms performed assessments at 3 and 6 months. SoC subjects 
could exit the trial after the 6-month evaluation and thereafter receive EBV treatment. Any 
subjects remaining in the SoC group (declining valve treatment after the 6-month follow up) 
was followed up at 12 months where after they would exit the study. In addition to the 3, 6, 
and 12 months follow-up visits, subjects in the EBV group will be followed-up at 45 days, 18 
and 24 months following valve placement.   
• Adverse events were solicited during each visit and during any unscheduled visit. 
 
 
Figure E3: Study Scheme 
 
V1: Screening 
V2: Bronchoscopy to determine CV status and randomization is CV negative (CV-) 
V3: 45 Day – HRCT for EBV group only 
V4: 3-month assessment 
V5: 6-month assessment; exit of SoC subjects if choosing to pursue EBV treatment 
V6: 12-month assessment 
V7: 18-month assessment – EBV only 
V8: 24-month assessment – EBV only 
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Section E3: Randomization 
Subjects were randomly assigned at a 2:1 ratio to the EBV treatment group or the SoC group 
during the bronchoscopy procedure. Once CV negative status was confirmed, two study 
participants were randomized to the EBV Treatment arm for every one (1) participant 
randomized to the SoC arm using a blocked design to assure the 2:1 balance from start. Each 
site was provided with sealed envelopes with consecutive numbering. The envelopes were 
brought into the bronchoscopy suite and the seal was broken once the CV negative status has 
been confirmed; the enclosed document was marked “EBV” or “SoC”.  
 
 
Section E4: Analysis population 
During statistical analysis of the study results the patient population may be divided into 
subgroups, for example:  
• Intention-to-treat (ITT): all patients included in the study whether or not treated 
according to protocol.  
• Per-protocol (PP): all patients that meet the following criteria: 
1.   Meets inclusion/exclusion criteria. Prospective deviations preapproved by Sponsor 
does not cause removal from the PP group. 
2.   Received treatment (EBV or SoC). Any valve removed has been replaced before 3-
month assessment. 
Safety analyses were performed on the ITT population. 
 
Section E5: Handling of Missing Data 
If the FEV1 (L) data from the 3-month follow-up visit have failed to be collected, then this 
subject’s data for this parameter was excluded from the statistical analysis. Available data for 
other measures was analyzed.   
For the Intention to Treat analyses, for a missed visit, values for all variables were imputed 
using the Last Observation Carried Forward (LOCF) method. For a completed visit, no 
imputation was done for a single missing variable.   
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Figure E4: CONSORT Flow Diagram 
 
 
 
 
  
 
Consented and assessed for eligibility 
N=273) 
Randomized 2:1  (EBV:SoC)  
(N=97) 
176 subjects excluded 
• 170 screen failures 
− 75 failed heterogeneity 
− 19 failed PFTs 
− 19 failed 6MWD 
− 28 CV positive 
− 29 other Inc./Exc. 
• 5 withdrew consent 
• 1 died 
3 Month Follow-up 
EBV Group 
(N=65) 
SoC Group 
(N=32) 
• 1 withdrew consent • 5 withdrew consent 
• 1 died 
•
• 31 active subjects 
− 1 did not complete 
follow-up per protocol 
• 59 active subjects  
− 8 did not complete 
follow-up per protocol 
 
6 Month Follow-up • 31 active subjects • 58 active subjects 
− 4 did not complete 
follow-up per protocol 
 
Subjects may EXIT study 
for EBV treatment 
Continue to 12 Months 
Continue to 12, 18 and 
24 Months 
• 1 withdrew consent 
Reasons for withdrawn consents 
• 5 EBV subjects before 3-month visit: 1 difficult anatomy for EBV placement; 1 experienced 2 pneumothoraces, 
worsening COPD; 2 for lack of perceived benefit; 1 non-compliant, withdrawn by Investigator 
• 1 SoC subject before 3-month visit: Pursue EBV commercially 
 
• 1 EBV subjects between 3 and 6-month visit: Worsening COPD, all valves removed, subject withdrew consent 
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Figure E5: Responders based on Target Lobe Volume Reduction of ≥350mL 
 
 
 
Legend for Figure E5: Each bar represents an individual subject. Blue bars represent subjects that had a 
Target Lobe Volume reduction of equal to or greater than 350mL. Black bars represent subjects who did 
not achieve a TLVR of ≥350mL.  Dotted line represents a target volume of 350mL. 
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Figure E6: Responders based on Minimal Clinically Important Difference for Forced Expiratory 
Volume in 1 Second (%) (ITT population) 
 
 
 
 
Legend for Figure E6: Each bar represents an individual subject. Blue bars represent subjects that met or 
exceeded the minimal clinical important difference (MCID) for FEV1 of ≥12% improvement in FEV1 (L).  
Black bars represent subjects who did not meet the MCID. Dotted line represents the MCID. 
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Figure E7: Responders based on Minimal Clinically Important Difference for Six-Minute Walk 
Distance (6MWD) in meters (ITT population) 
 
 
 
 
Legend for Figure E7: Each bar represents an individual subject. Blue bars represent subjects that met or 
exceeded the minimal clinical important difference (MCID) for 6-Minute Walk Distance (26 meters).  
Black bars represent subjects who did not meet the MCID. Dotted line represents the MCID. 
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Figure E8: Responders based on Minimal Clinically Important Difference for St. George’s 
Respiratory Questionnaire Score (points) (ITT population) 
 
 
 
 
Legend for Figure E8: Each bar represents an individual subject. Blue bars represent subjects that met or 
exceeded the minimal clinical important difference (MCID) for St. George’s Respiratory Questionnaire (- 
4 points). Black bars represent subjects who did not meet the MCID. Dotted line represents the MCID. 
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Figure E9: Pneumothorax Treatment Algorithm 
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Table E1: Baseline Absolute Values 
Variable Group n Mean SD Min Median Max 
t-test 
p-value 
Emphysema score EBV 65 69.28 9.30 42.00 70.00 88.00 0.692 
 SoC 32 68.42 11.23 41.00 70.00 86.00  
Heterogeneity index EBV 65 21.77 14.59 -17.00 20.00 64.00 0.252 
 SoC 32 25.50 15.79 5.00 22.50 63.00  
FEV1 (L) EBV 65 0.78 0.24 0.37 0.76 1.40 0.008 
 SoC 32 0.94 0.31 0.47 0.87 1.61  
FEV1 (% predicted) EBV 65 29.75 9.18 15.00 28.00 48.00 0.214 
 SoC 32 32.16 8.35 17.00 32.00 49.00  
RV (L) EBV 64 5.47 1.26 3.10 5.38 8.37 0.764 
 SoC 32 5.39 1.16 3.36 5.29 8.56  
RV (% predicted) EBV 64 249.44 51.76 161.00 238.00 409.00 0.423 
 SoC 32 240.97 41.39 166.00 243.50 364.00  
TLC (L) EBV 64 8.12 1.54 5.30 8.13 12.49 0.200 
 SoC 32 8.55 1.56 5.74 8.74 11.12  
TLC (% predicted) EBV 64 138.97 18.88 102.00 136.50 209.00 0.648 
 SoC 32 137.28 12.48 117.00 139.00 163.00  
FEV1/FVC (%) EBV 65 32.70 8.13 18.90 31.46 56.17 0.508 
 SoC 32 31.57 7.32 19.48 31.03 49.12  
RV/TLC (%) EBV 64 67.20 7.79 50.58 68.09 87.16 0.016 
 SoC 32 63.13 7.47 52.08 62.63 78.46  
DLco (mmol/min/kPa) EBV 59 2.50 1.49 0.33 2.20 8.90 0.370 
 SoC 31 2.81 1.63 0.47 2.86 8.07  
DLco (% predicted) EBV 60 32.32 13.11 8.00 32.50 82.00 0.304 
 SoC 31 35.35 13.55 13.00 36.00 74.00  
SGRQ total score EBV 64 64.34 14.39 32.94 65.08 93.29 0.042 
 SoC 32 58.07 13.26 18.46 59.94 81.10  
6MWD (m) EBV 65 282.46 94.41 150.00 260.00 484.00 0.065 
 SoC 32 320.25 91.79 150.00 327.50 470.00  
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Table E1: Baseline Absolute Values 
Variable Group n Mean SD Min Median Max 
t-test 
p-value 
MRC breathlessness grade EBV 65 3.00 0.77 1.00 3.00 4.00 0.466 
 SoC 32 2.88 0.83 1.00 3.00 4.00  
BODE index EBV 65 6.14 1.68 3.00 6.00 9.00 0.116 
 SoC 31 5.55 1.77 3.00 5.00 9.00  
PaO2 (kPa) EBV 63 9.22 1.30 6.87 9.00 13.16 0.365 
 SoC 32 8.96 1.33 5.73 9.15 11.00  
PaCO2 (kPa) EBV 63 5.31 0.66 3.76 5.24 7.07 0.213 
 SoC 32 5.13 0.61 4.08 5.14 6.44  
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Table E2: Changes from Baseline to 3 Month Follow-up for ITT Population 
Variable Group n Mean SD Min Median Max 
t-test 
p-value 
Change (%) FEV1 (L) EBV 65 23.21 28.49 -21.93 19.67 125.00 <.001 
 SoC 31 -4.01 12.95 -36.61 -2.67 15.48  
Change FEV1 (L) EBV 65 0.15 0.20 -0.26 0.13 0.72 <.001 
 SoC 31 -0.05 0.14 -0.41 -0.02 0.14  
Change FEV1 (% predicted) EBV 65 6.22 8.03 -7.00 5.00 33.00 <.001 
 SoC 31 -1.61 5.08 -16.00 -1.00 7.00  
Change DLco (mmol/min/kPa) EBV 58 0.07 1.03 -5.19 0.14 2.33 0.723 
 SoC 29 0.00 0.57 -1.49 0.00 1.37  
Change DLco (% predicted) EBV 59 2.78 8.84 -30.00 3.00 28.00 0.062 
 SoC 29 -0.72 6.54 -17.00 0.00 15.00  
Change SGRQ total score EBV 60 -8.87 15.70 -48.88 -7.45 46.08 0.018 
 SoC 30 -1.22 10.44 -21.16 -3.65 28.31  
Change 6MWD (m) EBV 64 37.22 65.11 -125.00 39.00 197.00 <.001 
 SoC 29 -20.86 32.46 -118.00 -15.00 51.00  
Change MRC breathlessness 
grade 
EBV 64 -0.59 1.03 -3.00 0.00 2.00 0.002 
 SoC 32 0.03 0.59 -1.00 0.00 1.00  
Change BODE index EBV 63 -1.14 1.75 -6.00 -1.00 3.00 <.001 
 SoC 28 0.39 0.83 -1.00 0.00 2.00  
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Table E3: Changes from Baseline to 6 Month Follow-up for ITT Population 
Variable Group n Mean SD Min Median Max 
t-test 
p-value 
Change (%) FEV1 (L) EBV 64 20.70 29.58 -36.36 15.54 108.86 <.001 
 SoC 31 -8.64 13.03 -44.54 -6.67 13.79  
Change FEV1 (L) EBV 64 0.14 0.24 -0.40 0.11 0.86 <.001 
 SoC 31 -0.09 0.14 -0.53 -0.05 0.12  
Change FEV1 (% predicted) EBV 64 5.45 8.77 -16.00 4.00 29.00 <.001 
 SoC 31 -2.87 4.44 -14.00 -2.00 4.00  
Change DLco (mmol/min/kPa) EBV 58 0.09 1.42 -5.95 0.23 3.15 0.062 
 SoC 28 -0.47 0.99 -2.95 -0.15 0.86  
Change DLco (% predicted) EBV 59 4.02 12.39 -31.00 2.00 65.00 0.004 
 SoC 28 -3.60 7.74 -19.00 -2.00 10.00  
Change SGRQ total score EBV 62 -7.22 15.10 -33.57 -6.80 43.58 0.031 
 SoC 32 -0.70 10.36 -20.46 -0.12 25.97  
Change 6MWD (m) EBV 63 36.17 76.93 -175.00 29.00 230.00 <.001 
 SoC 31 -42.48 68.15 -236.00 -30.00 55.00  
Change MRC breathlessness 
grade 
EBV 64 -0.56 1.04 -3.00 0.00 1.00 0.010 
 SoC 31 0.00 0.86 -2.00 0.00 2.00  
Change BODE index EBV 61 -0.97 2.01 -6.00 -1.00 4.00 <.001 
 SoC 28 0.79 1.17 -1.00 0.50 3.00  
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Table E4: Changes from Baseline to 3 Month Follow-up for PP Population 
Variable Group n Mean SD Min Median Max 
t-test 
p-value 
Change (%) FEV1 (L) EBV 51 27.76 29.82 -21.93 23.29 125.00 <.001 
 SoC 30 -4.14 13.14 -36.61 -2.90 15.48  
Change FEV1 (L) EBV 51 0.18 0.21 -0.26 0.18 0.72 <.001 
 SoC 30 -0.05 0.14 -0.41 -0.02 0.14  
Change FEV1 (% predicted) EBV 51 7.52 8.49 -7.00 7.00 33.00 <.001 
 SoC 30 -1.67 5.16 -16.00 -1.00 7.00  
Change DLco (mmol/min/kPa) EBV 45 0.24 0.77 -1.81 0.27 2.33 0.155 
 SoC 28 0.00 0.58 -1.49 -0.01 1.37  
Change DLco (% predicted) EBV 45 4.02 8.55 -16.00 4.00 28.00 0.014 
 SoC 28 -0.74 6.66 -17.00 0.00 15.00  
Change SGRQ total score EBV 48 -10.73 16.65 -48.88 -10.35 46.08 0.008 
 SoC 28 -1.16 10.80 -21.16 -3.65 28.31  
Change 6MWD (m) EBV 50 47.80 66.60 -125.00 52.00 197.00 <.001 
 SoC 28 -21.61 32.81 -118.00 -15.00 51.00  
Change MRC breathlessness 
grade 
EBV 51 -0.67 1.11 -3.00 0.00 2.00 0.001 
 SoC 30 0.07 0.58 -1.00 0.00 1.00  
Change BODE index EBV 50 -1.38 1.84 -6.00 -1.00 3.00 <.001 
 SoC 27 0.41 0.84 -1.00 0.00 2.00  
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Table E5: Changes from Baseline to 6 Month Follow up for PP Population 
Variable Group n Mean SD Min Median Max 
t-test 
p-value 
Change (%) FEV1 (L) EBV 50* 25.05 31.33 -36.36 21.05 108.86 <.001 
 SoC 30 -8.92 13.16 -44.54 -6.90 13.79  
Change FEV1 (L) EBV 50 0.17 0.26 -0.40 0.15 0.86 <.001 
 SoC 30 -0.09 0.14 -0.53 -0.07 0.12  
Change FEV1 (% predicted) EBV 50 6.67 9.43 -16.00 5.00 29.00 <.001 
 SoC 30 -2.97 4.48 -14.00 -2.00 4.00  
Change DLco (mmol/min/kPa) EBV 45 -0.38 0.94 -2.85 0.46 3.15 <.001 
 SoC 27 -0.49 1.00 -2.95 -0.20 0.86  
Change DLco (% predicted) EBV 45 5.78 13.30 -31.00 6.00 65.00 0.001 
 SoC 27 -3.73 7.86 -19.00 -2.00 10.00  
Change SGRQ total score EBV 50 -8.89 16.06 -33.57 -10.11 43.58 0.014 
 SoC 30 -0.60 10.69 -20.46 -0.12 25.97  
Change 6MWD (m) EBV 49 47.71 82.82 -175.00 53.00 230.00 <.001 
 SoC 29 -44.31 70.03 -236.00 -30.00 55.00  
Change MRC breathlessness 
grade 
EBV 51 -0.65 1.13 -3.00 -1.00 1.00 0.006 
 SoC 29 0.03 0.87 -2.00 0.00 2.00  
Change BODE index EBV 48 -1.21 2.18 -6.00 -1.00 4.00 <.001 
 SoC 27 0.81 1.18 -1.00 1.00 3.00  
*Consort diagram in figure E4 shows 51 EBV patients completed the study. FEV1 was not recorded for 1 
subject at 6 months. All other assessments were completed. For the PP population, LOCF was only done for 
FEV1 where none of the data for a visit was available i.e. there was a missed visit.  
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Table E6: Difference between groups for Changes from Baseline to 3 Month Follow up for 
ITT Population 
Variable Group Mean SD 95% CI 
t-test 
p-value 
Change (%) FEV1 (L) Δ EBV-SoC 27.22 24.62 16.55 - 37.89 <.001 
Change FEV1 (L) Δ EBV-SoC 0.20 0.18 0.12 - 0.28 <.001 
Change FEV1 (% predicted) Δ EBV-SoC 7.83 7.22 4.70 - 10.96 <.001 
Change DLco (mmol/min/kPa) Δ EBV-SoC 0.07 0.09 -0.34 - 0.48 0.723 
Change DLco (% predicted) Δ EBV-SoC 3.50 8.16 -0.18 - 7.18 0.062 
Change (%) RV (L) Δ EBV-SoC -10.59 14.68 -17.04 - -4.13 0.002 
Change RV (L) Δ EBV-SoC -0.58 0.84 -0.95 - -0.21 0.002 
Change RV (% predicted) Δ EBV-SoC -28.33 38.85 -45.40 - -11.26 0.001 
Change FEV1/FVC (%) Δ EBV-SoC 2.3 5.8 -0.2 - 4.8 0.074 
Change RV/TLC (%) Δ EBV-SoC -5.2 7.3 -8.4 - -2.0 0.002 
Change SGRQ total score Δ EBV-SoC -7.64 14.18 -13.95 - -1.34 0.018 
Change 6MWD (m) Δ EBV-SoC 58.08 57.09 32.70 - 83.46 <.001 
Change MRC breathlessness grade Δ EBV-SoC -0.63 0.91 -1.02 - -0.23 0.003 
Change BODE index Δ EBV-SoC -1.54 1.53 -2.23 - -0.85 <.001 
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Table E7: Difference between groups for Changes from Baseline to 6 Month Follow up for 
ITT Population 
Variable Group Mean SD 95% CI 
t-test 
p-value 
Change (%) FEV1 (L) Δ EBV-SoC 29.34 25.44 18.28 - 40.39 <.001  
Change FEV1 (L) Δ EBV-SoC 0.23 0.21 0.14 - 0.32 <.001  
Change FEV1 (% predicted) Δ EBV-SoC 8.32 7.65 4.99 - 11.64 <.001  
Change DLco (mmol/min/kPa) Δ EBV-SoC 0.56 1.30 -0.03 - 1.16 0.062  
Change DLco (% predicted) Δ EBV-SoC 7.62 11.12 2.55 - 12.70 0.004  
Change (%) RV (L) Δ EBV-SoC -13.10 17.55 -20.73 - -5.48 <.001  
Change RV (L) Δ EBV-SoC -0.67 0.97 -1.09 - -0.25 0.002  
Change RV (% predicted) Δ EBV-SoC -32.41 44.67 -51.82 - -13.00 0.001  
Change FEV1/FVC (%) Δ EBV-SoC 2.9 5.2 0.7 - 5.2 0.011  
Change RV/TLC (%) Δ EBV-SoC -6.4 7.7 -9.7 - -3.0 <.001  
Change SGRQ total score Δ EBV-SoC -6.52 13.69 -12.44 - -0.61 0.031  
Change 6MWD (m) Δ EBV-SoC 78.66 74.18 46.34 - 110.98 <.001  
Change MRC breathlessness grade Δ EBV-SoC -0.56 0.98 -0.99 - -0.14 0.010  
Change BODE index Δ EBV-SoC -1.75 1.79 -2.56 - -0.94 <.001 
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Table E8: Difference between groups for Changes from Baseline to 3 Month Follow up for 
PP Population 
Variable Group Mean SD 95% CI 
t-test 
p-value 
Change (%) FEV1 (L) Δ EBV-SoC 31.90 25.02 20.44 - 43.36 <.001 
Change FEV1 (L) Δ EBV-SoC 0.23 0.19 0.14 - 0.32 <.001 
Change FEV1 (% predicted) Δ EBV-SoC 9.19 7.44 5.78 - 12.60 <.001 
Change DLco (mmol/min/kPa) Δ EBV-SoC 0.24 0.71 -0.09 - 0.58 0.155 
Change DLco (% predicted) Δ EBV-SoC 4.76 7.88 0.98 - 8.54 0.014 
Change (%) RV (L) Δ EBV-SoC -12.40 14.96 -19.36 - -5.45 <.001 
Change RV (L) Δ EBV-SoC -0.67 0.84 -1.06 - -0.28 0.001 
Change RV (% predicted) Δ EBV-SoC -33.67 39.83 -52.18 - -15.16 <.001 
Change FEV1/FVC (%) Δ EBV-SoC 2.8 6.2 -0.0 - 5.7 0.051 
Change RV/TLC (%) Δ EBV-SoC -6.0 7.4 -9.5 - -2.5 <.001 
Change SGRQ total score Δ EBV-SoC -9.57 14.79 -16.57 - -2.56 0.008 
Change 6MWD (m) Δ EBV-SoC 69.41 56.94 42.64 - 96.17 <.001 
Change MRC breathlessness grade Δ EBV-SoC -0.73 0.95 -1.17 - -0.30 0.001 
Change BODE index Δ EBV-SoC -1.79 1.57 -2.53 - -1.04 <.001 
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Table E9: Difference between groups for Changes from Baseline to 6 Month Follow up for PP 
Population 
Variable Group Mean SD 95% CI 
t-test 
p-value 
Change (%) FEV1 (L) Δ EBV-SoC 33.98 26.09 21.98 - 45.97 <.001 
Change FEV1 (L) Δ EBV-SoC 0.26 0.22 0.16 - 0.36 <.001 
Change FEV1 (% predicted) Δ EBV-SoC 9.64 7.96 5.98 - 13.30 <.001 
Change DLco (mmol/min/kPa) Δ EBV-SoC 0.87 0.96 -0.41 - 1.34 <.001 
Change DLco (% predicted) Δ EBV-SoC 9.51 11.58 3.89 - 15.13 0.001 
Change (%) RV (L) Δ EBV-SoC -15.25 18.20 -23.62 - -6.89 <.001 
Change RV (L) Δ EBV-SoC -0.78 0.99 -1.24 - -0.33 <.001 
Change RV (% predicted) Δ EBV-SoC -38.77 45.73 -59.79 - -17.74 <.001 
Change FEV1/FVC (%) Δ EBV-SoC 3.2 5.5 0.7 - 5.7 0.014 
Change RV/TLC (%) Δ EBV-SoC -7.6 7.9 -11.2 - -4.0 <.001 
Change SGRQ total score Δ EBV-SoC -8.29 14.31 -14.87 - -1.71 0.014 
Change 6MWD (m) Δ EBV-SoC 92.02 78.35 55.46 - 128.58 <.001 
Change MRC breathlessness grade Δ EBV-SoC -0.68 1.04 -1.16 - -0.20 0.006 
Change BODE index Δ EBV-SoC -2.02 1.89 -2.93 - -1.12 <.001 
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Table E10: MCID responders for key outcome measures in the PP population at 6 months 
Variable EBV Group SoC Group p-value* 
FEV1 (L): (MCID ≥ +12%) 33/50 (66.0%) 1/30 (3.3%) < 0.001 
RV (ml): (MCID ≤ -430 mL) 34/50 (68.0%) 8/30 (26.7%) <0.001 
SGRQ: (MCID ≤ -4 points) 33/50 (66.0%) 10/30 (33.3%) 0.005 
6MWD: (MCID≥ +26 meters) 32/49 (65.3%) 4/29 (13.8%) <0.001 
mMRC: (MCID ≤ -1 point) 26/51 (51.0%) 6/29 (20.7%) 0.008 
FEV1: Forced Expiratory Volume in 1 second; RV: Residual Volume; SGRQ: Sr. George’s 
Respiratory Questionnaire’ 6MWD: Six Minute Walk Distance; mMRC: Modified 
Medical Research Council Dyspnea score 
*: Chi-squared test 
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Table E11: Respiratory Adverse Events over 6 Months 
 Adverse Events Subjects with Adverse Events 
Event 
EBV 
No. of 
events  
EBV  
% of 
events 
SoC 
No. of 
events 
SoC 
 % of 
events 
Fisher 
p-valve 
EBV  
No. of 
subjects 
EBV 
 % of 
subjects 
SoC  
No. of 
subjects 
SoC  
% of 
subjects 
Fisher 
p-
value 
Respiratory AEs 148 96.1 26 57.8 <.001 59 90.8 13 40.6 <.001 
Bleeding bulla right lung 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Bronchitis 1 1.5 1 3.1 1.000 1 1.5 1 3.1 1.000 
Bronchospasm 2 3.0 1 3.1 1.000 1 1.5 1 3.1 1.000 
COPD Exacerbation 39 48.8 13 36.1 0.231 24 36.9 9 28.1 0.496 
Chest infection 10 14.5 5 14.3 1.000 6 9.2 2 6.3 1.000 
Chest pain 6 9.2 0 0.0 0.173 6 9.2 0 0.0 0.173 
Common cold 2 3.1 0 0.0 1.000 2 3.1 0 0.0 1.000 
Cough 4 6.2 0 0.0 0.299 4 6.2 0 0.0 0.299 
Desaturation 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Dyspnea 23 32.4 1 3.1 <.001 17 26.2 1 3.1 0.005 
EBV removal 2 3.1 0 0.0 1.000 2 3.1 0 0.0 1.000 
Emphysema 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Hemoptysis 4 6.2 0 0.0 0.299 4 6.2 0 0.0 0.299 
Hyperventilation 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Influenza 1 1.5 1 3.1 1.000 1 1.5 1 3.1 1.000 
Inhaled foreign body 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Lower Respiratory Tract Infection 2 3.1 0 0.0 1.000 2 3.1 0 0.0 1.000 
Mucus 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Mucus production 3 4.6 0 0.0 0.549 3 4.6 0 0.0 0.549 
Pneumonia 8 12.1 1 3.1 0.264 7 10.8 1 3.1 0.265 
Pneumothorax 20 30.3 0 0.0 <.001 19 29.2 0 0.0 <.001 
Post-operative pain 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Pulmonary infection 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Purulent Sputum 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Quincke's Oedema of the Lingula 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Respiratory infection 2 3.1 0 0.0 1.000 2 3.1 0 0.0 1.000 
Sinusitis 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Sore throat 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Thoracic pain 4 6.2 0 0.0 0.299 4 6.2 0 0.0 0.299 
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Table E11: Respiratory Adverse Events over 6 Months 
 Adverse Events Subjects with Adverse Events 
Event 
EBV 
No. of 
events  
EBV  
% of 
events 
SoC 
No. of 
events 
SoC 
 % of 
events 
Fisher 
p-valve 
EBV  
No. of 
subjects 
EBV 
 % of 
subjects 
SoC  
No. of 
subjects 
SoC  
% of 
subjects 
Fisher 
p-
value 
Upper Respiratory Tract Infection 4 6.1 0 0.0 0.300 3 4.6 0 0.0 0.549 
Valve dislocation 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Wheezing 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
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Table E12: Non-Respiratory Adverse Events over 6 Months 
 Adverse Events Subjects with Adverse Events 
Event 
EBV 
No. of 
events  
EBV  
% of 
events 
SoC 
No. of 
events 
SoC 
 % of 
events 
Fisher 
p-valve 
EBV  
No. of 
subjects 
EBV 
 % of 
subjects 
SoC  
No. of 
subjects 
SoC  
% of 
subjects 
Fisher 
p-
value 
Non-Respiratory AEs 43 50.0 12 33.3 0.112 22 33.8 8 25.0 0.485 
Abdominal pain 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Allergic reaction 2 3.0 0 0.0 1.000 1 1.5 0 0.0 1.000 
Anxiety 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Asthenia 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Back pain 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Bruises left side arms and legs 
(traffic accident) 
1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Chronic flebothrombosis 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Cushingoid face 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Diarrhea 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Diverticulitis 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Dizziness 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Edema 3 4.5 0 0.0 0.549 2 3.1 0 0.0 1.000 
Fever 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Foot fracture 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Fungal infection 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Gastric reflux 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Headache 2 3.1 0 0.0 1.000 2 3.1 0 0.0 1.000 
Heart failure 2 3.1 0 0.0 1.000 2 3.1 0 0.0 1.000 
Hoarseness 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Hypercholesterolemia 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Hypertension 3 4.6 1 3.1 1.000 3 4.6 1 3.1 1.000 
Hyperthyroidism 1 1.5 1 3.1 1.000 1 1.5 1 3.1 1.000 
Hypotension 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Mucositis 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Musculoskeletal event 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Nausea 2 3.1 0 0.0 1.000 2 3.1 0 0.0 1.000 
Radiomucositis 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Rheumatoid arthritis 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
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Table E12: Non-Respiratory Adverse Events over 6 Months 
 Adverse Events Subjects with Adverse Events 
Event 
EBV 
No. of 
events  
EBV  
% of 
events 
SoC 
No. of 
events 
SoC 
 % of 
events 
Fisher 
p-valve 
EBV  
No. of 
subjects 
EBV 
 % of 
subjects 
SoC  
No. of 
subjects 
SoC  
% of 
subjects 
Fisher 
p-
value 
Rib fracture 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Right shoulder pain 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Skin rash 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Squamous carcinoma 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Supraventricular tachycardia 2 3.1 0 0.0 1.000 2 3.1 0 0.0 1.000 
Throat pain 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Tiredness 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Tooth pain 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Unspecified infection 3 4.6 0 0.0 0.549 3 4.6 0 0.0 0.549 
Urinary tract infection 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Urosepsis 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Vertebral fracture 0 0.0 1 3.1 0.330 0 0.0 1 3.1 0.330 
Viral infection 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
Wound infection 1 1.5 0 0.0 1.000 1 1.5 0 0.0 1.000 
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Table E13: Occurrence of Pneumothorax by Lobe Treated 
Treated lobe 
Number of subjects 
with pneumothorax 
Total number of 
subjects treated 
per lobe 
% Subjects with 
pneumothorax 
by Lobe Treated 
LUL 11 (12 events) 34 32.4 
LLL 6 14 42.9 
RUL 2 10 20.0 
RUL+RML 0 5 0.0 
RLL 0 2 0.0 
Total 19 (20 events) 65 
 
 
 
 
 
 
 
 
 
 
Table E14: EBV Subjects with Pneumothorax and No Pneumothorax: Difference 
between groups for Changes from Baseline to 3 Month Follow up (ITT)  
Variable Group Mean SD 95% CI 
t-test 
p-value 
Change (%) FEV1 (L) Δ Pneu-No Pneu 1.17 28.71 -14.48 - 16.81 0.882 
Change FEV1 (L) Δ Pneu-No Pneu 0.02 0.20 -0.09 - 0.13 0.764 
Change FEV1 (% predicted) Δ Pneu-No Pneu 0.27 8.09 -4.14 - 4.69 0.901 
Change DLco (mmol/min/kPa) Δ Pneu-No Pneu 0.02 1.04 -0.58 - 0.62 0.941 
Change DLco (% predicted) Δ Pneu-No Pneu 0.42 8.92 -4.71 - 5.55 0.870 
Change SGRQ total score Δ Pneu-No Pneu -1.07 15.82 -9.99 - 7.86 0.812 
Change 6MWD (m) Δ Pneu-No Pneu 18.71 65.07 -17.45 - 54.87 0.305 
Change MRC breathlessness grade Δ Pneu-No Pneu -0.18 1.04 -0.76 - 0.40 0.351 
Change BODE index Δ Pneu-No Pneu -0.61 1.74 -1.60 - 0.38 0.174 
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Table E15: EBV Subjects with Pneumothorax and No Pneumothorax: Difference 
between groups for Changes from Baseline to 6 Month Follow up (ITT) 
Variable Group Mean SD 95% CI 
t-test 
p-value 
Change (%) FEV1 (L) Δ Pneu-No Pneu 4.70 29.74 -11.56 - 20.96 0.566 
Change FEV1 (L) Δ Pneu-No Pneu 0.04 0.24 -0.09 - 0.17 0.567 
Change FEV1 (% predicted) Δ Pneu-No Pneu 1.53 8.82 -3.29 - 6.35 0.529 
Change DLco (mmol/min/kPa) Δ Pneu-No Pneu 0.11 1.43 -0.72 - 0.94 0.787 
Change DLco (% predicted) Δ Pneu-No Pneu -1.90 12.46 -9.08 - 5.27 0.598 
Change SGRQ total score Δ Pneu-No Pneu 1.69 15.21 -6.82 - 10.20 0.693 
Change 6MWD (m) Δ Pneu-No Pneu 2.99 77.55 -39.58 - 45.56 0.889 
Change MRC breathlessness grade Δ Pneu-No Pneu -0.22 1.04 -0.80 - 0.36 0.307 
Change BODE index Δ Pneu-No Pneu -0.20 2.02 -1.34 - 0.93 0.546 
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